NCT07081503

Phase 1 Study of ADX-626 in Healthy Participants

A Phase 1, Randomized, Blinded, Placebo-Controlled Study to Assess ADX-626 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: ADARx Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Detailed description

A Phase 1, first-in-human study to assess the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-626 compared with placebo in healthy participants.

Conditions

• Healthy Adult Participants

Interventions

Type	Name	Description
DRUG	ADX-626	siRNA duplex oligonucleotide
DRUG	Placebo	Saline

Timeline

• Start date: 2025-08-12
• Primary completion: 2027-01-22
• Completion: 2027-01-22
• First posted: 2025-07-23
• Last updated: 2026-03-02

Locations

1 site across 1 country: United Kingdom